# US 2013/0274444 A1 · Process for production of fibrinogen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274444 A1
- Document ID: US20130274444A1
- Status: Published application
- Kind: A1
- Application number: 13/825,317
- Filed: 2011-09-20
- Published: 2013-10-17
- Earliest claimed: 2010-09-20
- Assignees: Octapharma AG
- Inventors: Petra Schulz; Rainer Pape; Werner Gehringer
- Web page: https://patentgrep.com/patent/US20130274444A1

## CPC

- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 1/18: Ion-exchange chromatography
- C07K 1/36: by a combination of two or more processes of different types
- C07K 14/75: Fibrinogen
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.

## Claims

### Claim 1

A process for purifying fibrinogen from a fibrinogen containing source, comprising subjecting a fibrinogen containing solution to chromatography on anion exchange resins, wherein the anion exchange resins are selected from the group consisting of a support material comprising a hydroxylated polymer with grafted tertiary or quaternary amino groups.

### Claim 2 (depends on 1)

The process of claim 1, wherein the support material is composed of cellulose, agarose, silica, polymeric or ceramic material.

### Claim 3 (depends on 1)

The process of claim 1, wherein the anion-exchange resin is trimethyl-amino groups grafted to a hydroxylated methacrylic polymer via a linking group, such as GigaCap Q-650M®.

### Claim 4 (depends on 1)

The process of claim 1, wherein the fibrinogen containing source is cryoprecipitate, preferably solubilised at about neutral pH .

### Claim 5 (depends on 4)

The process of claim 4, wherein the solution is treated with Al(OH)3 and the resulting gel is removed.

### Claim 6 (depends on 4)

The process of claim 4 wherein a virus inactivation is performed by employing a solvent/detergent (S/D) treatment.

### Claim 7 (depends on 6)

The process of claim 6 wherein an extraction of S/D reagents with vegetable oil and contacting the water-phase with a TMAE resin at a pH-value of 6.9-7.1 and an osmolality of 570-610 mosmol/l is performed.

### Claim 8 (depends on 6)

The process of claim 6, wherein fibrinogen is precipitated by glycine, in particular about 1 M glycine, and separation of the formed fibrinogen paste.

### Claim 9 (depends on 8)

The process of claim 8 wherein the fibrinogen paste is resuspended, preferably in about 20 mM TRIS buffer at a pH of about 8.0.

### Claim 10 (depends on 9)

The process of claim 9 wherein after filtration the obtained fraction is loaded onto a strong anion exchange resin comprising trimethyl-amino groups grafted to a hydroxylated methacrylic polymer backbone via linking groups and washing off loosely bound substances, preferably with a wash buffer of about 12.0 mS/cm conductivity.

### Claim 11 (depends on 10)

The process of claim 10 wherein fibrinogen is eluted with an elution buffer containing sodium citrate, sodium chloride, and glycine, preferably about 1.5 g/l sodium citrate, about 7.0 g/l sodium chloride and about 10.0 g/l glycine, in particular adjusted to a pH of about 7.0 and a conductivity of 13.1-15 mS/cm.

### Claim 12 (depends on 11)

The process of claim 11, wherein the obtained fraction is concentrated, formulated, sterile filtered and/or filled.

### Claim 13 (depends on 12)

The process of claim 12, wherein the obtained fraction is lyophilised.

### Claim 14 (depends on 1)

The process of claim 1 comprising the steps of
a) solubilisation of cryoprecipitate, solubilised at about neutral pH,
b) subjecting the solution to adsorption with AI(OH)3 and removing the resulting gel,
c) virus inactivating the resulting solution of step b) by a solvent/detergent (S/D) treatment, extraction of S/D reagents with vegetable oil and contacting the water-phase with a TMAE resin at a pH-value of 6.9-7.1 and an osmolality of 570-610 mosmol/l,
d) precipitation of fibrinogen, which is found in the flow-through or supernatant of step c), by about 1 M glycine, and separation of the fibrinogen paste,
e) resuspention of the fibrinogen paste in a 20 mM TRIS buffer at a pH of about 8.0, filtration and,
f) loading the filtered solution of step e) onto a strong anion exchange resin comprising trimethylamino groups grafted to a hydroxylated methacrylic polymer backbone via linking groups and washing off loosely bound substances with a wash buffer of about 12.0 mS/cm conductivity,
g) elution of fibrinogen with an elution buffer containing about 1.5 g/l sodium citrate, about 7.0 g/l sodium chloride and about 10.0 g/l glycine, in particular adjusted to a pH of about 7.0 and a conductivity of 13.1-15 mS/cm,
h) concentrating, formulating, sterile filtering and filling.

### Claim 15 (depends on 1)

A fibrinogen product obtainable according to claim 1.

### Claim 16 (depends on 15)

The fibrinogen product of claim 15 having fibronectin content of 0.01-1.00 μg/mg per fibrinogen obtainable by a process comprising the following steps:
a) solubilisation of cryoprecipitate, solubilised at about neutral pH,
b) subjecting the solution to adsorption with Al(OH)3 and removing the resulting gel,
c) virus inactivating the resulting solution of step b) by a solvent/detergent (S/D) treatment with Triton and TnBP, extraction of S/D reagents with vegetable oil and contacting the water-phase with a TMAE resin at a pH-value of 6.9-7.1 and an osmolality of 570-610 mosmol/l,
d) precipitation of fibrinogen, which is found in the flow-through or supernatant of step c), by 1 M glycine, and separation of the fibrinogen paste,
e) resuspention of the fibrinogen paste in a 20 mM TRIS buffer at a pH of about 8.0, filtration and,
f) loading the filtered solution of step e) onto a strong anion exchange resin comprising trimethyl-amino groups grafted to a hydroxylated methacrylic polymer backbone via linking groups and washing off loosely bound substances with a wash buffer of about 12.0 mS/cm conductivity,
g) elution of fibrinogen with an elution buffer containing about 1.5 g/l sodium citrate, about 7.0 g/1 sodium chloride and about 10.0 g/l glycine, in particular adjusted to a pH of about 7.0 and a conductivity of 13.1-15 mS/cm,
h) concentrating, formulating, sterile filtering and filling.

### Claim 17 (depends on 15)

The fibrinogen product of claim 15, wherein the fibrinopeptide-A content is 0.01-9.0 ng/mg fibrinogen, the VWF:Ag activity is less than 0.1 IU/mg fibrinogen, the factor XIII activity is 0.07-1 IU/mg fibrinogen or a thrombin activity of less than 0.007 IU/mg fibrinogen.

### Claim 18 (depends on 15)

The fibrinogen product of claim 15 having the following properties:
Fibrinogen Clauss (turbidimetric)
20-26.0
[mg/ml]
mg Fibrinogen-Antigen/mg Fibr.-Clauss
0.8-1.2
IU F XIII/mg Fibr.-Clauss
0.09-0.14
μg Fibronectin/mg Fibr.-Clauss
0.1-1.0
ng Fibrinopeptide A/mg Fibr.-Clauss
0.3-5.0

### Claim 19 (depends on 15)

The fibrinogen of claim 15, characterized in that it is in lyophilized state.

### Claim 20 (depends on 1)

A method of using an anion exchange resin for purification or manufacturing of a fibrinogen product comprising carrying out the process of claim 1.
